Peptide News Digest

#Hengrui-Pharma

4 stories

Industry · View digest

Kailera Pipeline Update: Injectable Ribupatide in Global Phase 3, Oral KAI-7535 in Global Phase 2, Both Licensed From Hengrui

Kailera Therapeutics (NASDAQ: KLRA) holds rights outside Greater China to several Hengrui Pharma obesity drugs. Ribupatide (KAI-9531), a once-weekly injectable GLP-1/GIP dual agonist, is in the three-trial global KaiNETIC Phase 3 program, which had enrolled more than 4,700 participants as of August 12, 2026, testing doses up to 10 mg over 76 weeks with data expected in 2028. KAI-7535 (HRS-7535) is a separate drug, a once-daily oral small-molecule GLP-1 receptor agonist, now in a roughly 320-person global Phase 2 trial in the U.S. and Australia with data expected in 2027; Kailera's GLP-1/GIP/glucagon triple agonist is a third drug, HRS-4729.

Regulatory · View digest

Hengrui HRS-7535 Oral GLP-1 Receptor Agonist NMPA Marketing Authorization Application Accepted in China for Obesity and Type 2 Diabetes

Hengrui Pharma (SHA: 600276, HKEX: 1276) disclosed Wednesday September 2, 2026 that China's National Medical Products Administration (NMPA) accepted the marketing authorization application for HRS-7535 (an oral once-daily small-molecule GLP-1 receptor agonist) for long-term weight management in adults with obesity or overweight, plus a separate marketing authorization application for HRS-7535 in type 2 diabetes based on the Phase 3 OUTSTAND-1 and OUTSTAND-2 trials. The Chinese Phase 3 obesity trial delivered mean weight loss of up to 10.9% at Week 44 (11.1% at Week 50 with continued treatment) versus 2.5% for placebo in the 180 mg group. If approved, HRS-7535 would become the first oral small-molecule GLP-1 receptor agonist marketed in China. HRS-7535 is licensed to Kailera Therapeutics (NASDAQ: KLRA) for global rights outside Greater China; the U.S. Phase 3 program is planned to initiate imminently. HRS-7535 would compete with Novo Nordisk's Wegovy pill (oral semaglutide) and Eli Lilly's Foundayo (orforglipron) in oral obesity therapeutics.

Regulatory · View digest

Hengrui Pharma Disclosed Saturday August 22, 2026 That China's Center for Drug Evaluation (CDE) Granted Implied License for HRS-4729 in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) and Hepatitis, Extending Hengrui's Cardiometabolic Pipeline Beyond Its Existing Ribupatide (GLP-1/GIP Dual Agonist Licensed Ex-China to Kailera Therapeutics, in Global Phase 3) Into the Growing MASH Commercial Category That Is Anchored Commercially by Madrigal Pharmaceuticals' Rezdiffra (Resmetirom, First MASH Drug Approved March 2024) and Novo Nordisk's Wegovy (Semaglutide 2.4 mg, First GLP-1 Receptor Agonist Approved for MASH in August 2025); The Hengrui CDE Implied License Provides Approval to Initiate Human Clinical Trials in China Under a Simplified Regulatory Pathway

Hengrui Pharma disclosed Saturday August 22, 2026 that China's Center for Drug Evaluation (CDE) granted implied license for HRS-4729 in metabolic dysfunction-associated fatty liver disease (MAFLD) and hepatitis. The CDE implied license is a Chinese regulatory instrument that provides approval to initiate human clinical trials in China under a simplified pathway (similar in function to a US Investigational New Drug application, though procedurally different). Kailera, which licensed the drug outside Greater China as KAI-4729, described it in its August 12, 2026 results as a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist. The disclosure extends Hengrui's cardiometabolic pipeline beyond its existing ribupatide (once-weekly injectable GLP-1/GIP dual agonist licensed ex-China to Kailera Therapeutics and in the global Phase 3 KaiNETIC program) into the growing MASH commercial category. MASH commercial market context: the category is anchored by Madrigal Pharmaceuticals' Rezdiffra (resmetirom, a thyroid hormone receptor beta agonist and the first FDA-approved MASH drug, approved March 2024) and Novo Nordisk's Wegovy (semaglutide 2.4 mg received FDA accelerated approval for non-cirrhotic MASH with moderate-to-advanced fibrosis in August 2025). The Hengrui advance into MAFLD/hepatitis positions the company for a potential fourth cardiometabolic franchise beyond obesity, type 2 diabetes, and cardiovascular disease.

Clinical Trials · View digest

Kailera Therapeutics (NASDAQ: KLRA) Reported August 12 Q2 2026 Financial Results and Disclosed an Active Investigational New Drug (IND) Application With the US FDA for Ribupatide Oral (KAI-9531-T), a GLP-1/GIP Dual Agonist Peptide for Obesity Being Co-Developed With Hengrui Pharma, With Global Phase 3 Obesity Trials Planned to Initiate in H1 2027 Following Hengrui's Phase 2 Trial in Adults With Obesity That Documented Up to 12.1% Mean Weight Loss With No Observed Plateau at Week 26 and Up to 38.6% of Participants Achieving at Least 15% Weight Loss at the 25 mg and 50 mg Once-Daily Oral Doses; A Ribupatide Injection Phase 2b High-Dose Trial in Obesity Is Fully Enrolled With Data Anticipated in Mid-2027

Kailera Therapeutics (NASDAQ: KLRA) reported August 12, 2026 Q2 2026 financial results and disclosed an active Investigational New Drug (IND) application with the US FDA for ribupatide oral (KAI-9531-T), a once-daily form of the GLP-1/GIP dual agonist peptide ribupatide for obesity, being co-developed with Hengrui Pharma. Global Phase 3 obesity trials are planned to initiate in H1 2027. Phase 2 data foundation: Hengrui's Phase 2 trial in adults with obesity documented up to 12.1% mean weight loss with no observed plateau at Week 26 and up to 38.6% of participants achieving at least 15% weight loss at the 25 mg and 50 mg once-daily oral doses. A ribupatide injection Phase 2b high-dose trial in obesity is fully enrolled with data anticipated in mid-2027. Ribupatide acts on the same two receptors as Eli Lilly's tirzepatide, and its weekly injectable form is already in Kailera's global Phase 3 KaiNETIC program. The oral formulation could compete with Lilly's orforglipron (oral small-molecule GLP-1 agonist, roughly 7.5-11.2% weight loss over 72 weeks) and Novo Nordisk's Wegovy pill (oral semaglutide 25 mg). Kailera holds US and ex-China commercial rights via a license from Hengrui.